ASLAN Pharmaceuticals, a biotech company focused on the development of immunotherapies and targeted agents for Asia-prevalent tumour types, has announced that it has won the inaugural BioSingapore Innovative Biomedical Company award.
The award, presented by BioSingapore, recognises Singapore-based biomedical companies that are at the forefront of innovation, and have demonstrated growth and sustainable business practices.
The award caps a year of significant developments for ASLAN as the company prepares itself for a public listing on the Taipei Exchange later this year.
In 2016, ASLAN closed a pre-IPO financing round of $23 million. The company forged new strategic collaborations with leading research institutions and commercial partners, including inlicensing deals to expand its existing pipeline to build a proprietary portfolio of innovative oncology programmes.
ASLAN also received an orphan drug designation for its lead asset for gastric cancer.
Dr Carl Firth, Chief Executive Officer of ASLAN Pharmaceuticals, said: “My team and I are proud to be recognised with this award, which comes at a time when ASLAN is about to enter an exciting and pivotal new phase in its growth.”
“The many new collaborations and rapid advancements in our pipeline would not have been possible without the immense work undertaken by my colleagues, or the support we have received from our partners and investors. We are grateful for this mark of confidence in all that ASLAN has achieved.”
The award was presented at the BioPharma Industry Awards ceremony on 22 March 2017, as part of the BioPharma Asia 2017 convention. This is the second consecutive year that ASLAN has been honoured at the awards. Last year, ASLAN was named Asian Biotech of the Year.